Novo Nordisk A/S Sponsored ADR (NVO)
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of deceptive pricing practices, court papers on Monday show.
Novo Nordisk shares surge on positive weight loss drug trial results
Novo Nordisk (NYSE:NVO) stock added more than 7% on Friday after the Danish drugmaker unveiled positive early-stage trial results for its weight loss drug amycretin. The trial demonstrated that patients receiving the highest dose of amycretin, a unimolecular long-acting GLP-1 and amylin receptor agonist, achieved an average weight loss of 22% after 36 weeks.
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Finally, some good news for Novo Nordisk (NVO 7.30%) shareholders!
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's (NVO) U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
BA's $3.5B Loss, NVO Weight Loss Drug Trial, AXP Down on Strong Earnings
"It's difficult to find what we're not liking" for American Express's (AXP) earnings, says Jenny Horne. A strong report bolstered by a big holiday shopping season wasn't enough to impress investors.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVO Weight-Loss Drug Gets Positive Data
Novo Nordisk (NVO) pops on positive drug trial results. The company showed a 22% reduction in weight for obese and overweight patients after 36 weeks.
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
The Danish drugmaker announced new data for its new weight-loss drug Amycretin Friday.
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
